首頁 > 市場調查報告書 > 製藥

糖尿病

市場調查報告書

商品編碼

2076099

吉米格列汀市場：按藥物類型、分銷管道、最終用戶、患者群體和地區分類

Gemigliptin Market, By Type of Drug, By Distribution Channel, By End User, By Patient Demographics, By Geography

出版日期: 2026年04月29日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

吉米格列汀市場預計在 2026 年達到 21 億美元，預計到 2033 年將達到 30.8 億美元。預計從 2026 年到 2033 年，其複合年成長率將達到 5.6%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	21億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	5.60%	2033年市場規模預測：	30.8億美元

吉米格列汀是一種強效且選擇性的Dipeptidyl Peptidase-4 (DPP-4) 抑制劑，用於治療第2型糖尿病。憑藉其獨特的化學結構，吉米格列汀可透過增強腸促胰島素的作用有效降低血糖值。這種口服藥物透過促進葡萄糖依賴性胰島素分泌和抑制升糖素釋放，在血糖控制方面取得了顯著療效。作為DPP-4抑制劑領域的新成員，Gemigliptin的安全性和有效性使其成為尋求改善血糖控制和降低低血糖風險的糖尿病患者的理想選擇。其獨特的化學結構和作用機制使其有別於其他抗糖尿病藥物。Gemigliptin通常每日口服一次，為糖尿病患者提供了便利。然而，持續的研究、策略行銷以及製劑和聯合治療的潛在創新旨在將Gemigliptin定位為糖尿病管理各個領域的有效選擇。

市場動態：

糖尿病盛行率上升、公眾意識提高和診斷率提升，以及口服降血糖藥的普及，預計將推動全球Gemigliptin市場在預測期內成長。此外，有利的法規環境預計也將促進全球Gemigliptin市場在預測期內的成長。新興市場的擴張、聯合治療、以患者為中心的治療策略、兒童用藥以及妊娠期糖尿病的治療，預計將在預測期內為全球Gemigliptin市場創造成長機會。

然而，現有藥物的競爭、專利到期、學名藥的競爭以及安全問題預計將在預測期內阻礙Gemigliptin市場的成長。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數創建了Gemigliptin市場主要公司的概況：公司概況、產品系列、主要亮點、財務表現和策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
這份Gemigliptin市場報告的目標受群眾外包括行業內的各種相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用分析Gemigliptin市場中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第9章競爭情勢

Daewoong Pharmaceutical
Sanofi
LG Chem
Hanmi Pharmaceutical Co., Ltd.
Merck

第10章

調查方法
關於本公司

簡介目錄

Product Code: CMI6114

Gemigliptin Market is estimated to be valued at USD 2.10 Bn in 2026 and is expected to reach USD 3.08 Bn by 2033, growing at a compound annual growth rate (CAGR) of 5.6% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 2.10 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	5.60%	2033 Value Projection:	USD 3.08 Bn

Gemigliptin is a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor used in the management of type 2 diabetes mellitus. With its unique chemical structure, gemigliptin effectively lowers blood glucose levels by enhancing the action of incretin hormones. This oral medication offers promising results in gycemic control by promoting glucose-dependent insulin secretion and suppressing glucagon release. As a newer entrant in the DPP-4 inhibitor class, Gemigliptin's safety profile and efficacy make it a valuable option for diabetes patients seeking improved glucose regulation and a reduced risk of hypoglycaemia. This medication is characterized by its unique chemical structure and mechanism of action, setting it apart from other antidiabetic drugs. Gemigliptin is typically prescribed as a once-daily oral treatment, providing convenience for patients managing their diabetes. However, ongoing research, strategic marketing, and potential innovations in formulation or combination therapies aim to position gemigliptin as a valuable option in the diverse landscape of diabetes management.

Market Dynamics:

The rising prevalence of diabetes, increasing awareness and diagnosis, and shift towards oral antidiabetic drugs are anticipated to drive growth of the global gemigliptin market over the forecast period. Moreover, a favorable regulatory environment is also expected to boost the growth of the global gemigliptin market over the forecast period. Expansion in emerging markets, combination therapies, a focus on patient-centric approaches, pediatric use, and gestational diabetes are expected to create growth opportunities for the global gemigliptin market during the forecast period.

However, competition from established drugs, patent expiry, generic competition, and safety concerns are expected to hamper growth of the gemigliptin market over the forecast period.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the gemigliptin market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Daewoong Pharmaceutical, Sanofi, LG Chem, Hanmi Pharmaceutical Co., Ltd., and Merck
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The gemigliptin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the gemigliptin market

Detailed Segmentation:

Gemigliptin Market Segmentation, By Type of Drug (Revenue, USD Bn, 2021 - 2033)
Gemigliptin Monotherapy
Gemigliptin Combination Therapy
Gemigliptin Market Segmentation, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Gemigliptin Market Segmentation, By End User (Revenue, USD Bn, 2021 - 2033)
Hospitals
Clinics and Outpatient Facilities
Others (Academic and Research Institutes)
Gemigliptin Market Segmentation, By Patient Demographics (Revenue, USD Bn, 2021 - 2033)
Adult Population
Geriatric Population
Regional Insights (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Company Profile:
Daewoong Pharmaceutical
Sanofi
LG Chem
Hanmi Pharmaceutical Co., Ltd.
Merck

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Gemigliptin , By Type of Drug
- Market Gemigliptin , By Distribution Channel
- Market Gemigliptin , By End User
- Market Gemigliptin , By Patient Demographics
- Market Gemigliptin , By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
  - Rising prevalence of diabetes
- Restraints
  - Competition from established drugs
- Opportunities
  - Expansion in emerging markets
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Gemigliptin Market , By Type of Drug, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Gemigliptin Monotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
Gemigliptin Combination Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)

5. Gemigliptin Market , By Distribution Channel, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)

6. Gemigliptin Market , By End User, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
Retail Clinics and Outpatient Facilities
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
Others (Academic and Research Institutes)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)

7. Gemigliptin Market , By Patient Demographics, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Adult Population
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
Geriatric Population
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)

8. Gemigliptin Market , By Region, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, By Country, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Country 2022-2033
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2021 - 2033, (US$ Bn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Daewoong Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
LG Chem
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Hanmi Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Merck
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Analyst Views